Zimberelimab
- Generic Name
- Zimberelimab
- Drug Type
- Biotech
- CAS Number
- 2259860-24-5
- Unique Ingredient Identifier
- ZBL7O904IL
- Indication
用于治疗二线以上复发或难治性经典型霍奇金淋巴瘤（r/r cHL）患者。
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Phase 2
Recruiting
- Conditions
- Metastatic Urothelial Cancer
- Interventions
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 643
- Registration Number
- NCT03547973
- Locations
- 🇪🇸
Hospital Universitario Puera de Hierro Majadahonda, Majadahonda, Spain
🇪🇸CEIC Hospital Vall d'Hebron, Barcelona, Spain
🇺🇸The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath